Monoclonal Antibody Therapy
Monoclonal antibody therapy is a process in which monoclonal antibodies (mAb) are used to bind monospecifically to certain cells or proteins. This may then stimulate the patient's immune system to attack those cells. Alternatively, in radioimmunotherapy a radioactive dose localizes on a target cell line, delivering lethal chemical doses. More recently antibodies have been used to bind to molecules involved in T-cell regulation to remove inhibitory pathways that block T-cell responses, known as immune checkpoint therapy. It is possible to create a mAb specific to almost any extracellular/ cell surface target. Research and development is underway to create antibodies for diseases (such as rheumatoid arthritis, multiple sclerosis, Alzheimer's disease, Ebola and different types of cancers).
- Advantages in Monoclonal Antibody Therapy
- Monoclonal and Polyclonal antibodies
- Monoclonal Antibody Therapy for Cancer
- Monoclonal Antibodies Applications
- Hybridoma Technology and Monoclonal Antibody Preparation
- Antibody Research in Agriculture, Aquaculture, Veterinary and Food Sciences
- Antibody Technology in New Protein Discovery
Related Conference of Monoclonal Antibody Therapy
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
Monoclonal Antibody Therapy Conference Speakers
Recommended Sessions
- Anti-Cancer Antibodies
- Antibiotics
- Antibiotics used in Industries
- Antibiotics: Advances in Treatment
- Antibiotics: Applications
- Antibiotics: Clinical Trials
- Antibiotics: Infectious Diseases
- Antibiotics: Mechanism of Action
- Antibodies: Infectious Diseases
- Antibodies: Medical Applications
- Antibody Conjugate Therapeutics: Challenge and Potential
- Antibody Drug Therapy
- Antibody Engineering
- Antibody Humanization Technologies
- Auto Immune Antibodies
- Bio therapeutics : Early Analytical Development
- Bio Therapeutics: Novel Formulation and Delivery Approaches
- Cancer Immune therapy
- Emerging Protein Bio Therapeutics
- Immunotherapy and Immune Checkpoints
- Monoclonal Antibody Therapy
- Next-Generation Sequencing(NGS) in Antibody Discovery and Engineering: Overview and Applications
- Protein Engineering and Genetic Engineering
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
